期刊文献+

乳腺癌治疗过程中激素受体、HER2受体转变一例

原文传递
导出
摘要 1病史介绍 患者,女,57岁,因发现左乳肿物4+月就诊于北京世纪坛医院(2010年9月20日),行左乳肿物穿刺病理报告:浸润性导管癌,组织学分级II级,雌激素受体( estrogen receptor ,ER)(+),孕激素受体(progesterone receptor,PR)(+),人表皮生长因子受体2(human epidermal growth factor-2,HER2)(+++),原位免疫荧光杂交( fluorescent in situ hybridization ,FISH)检查示扩增,Ki6740%。
出处 《中华内分泌外科杂志》 CAS 2015年第2期171-172,共2页 Chinese Journal of Endocrine Surgery
  • 相关文献

参考文献11

  • 1Vant VL, Dai H, van de Vijver MJ, et al. Gene expression profi-ling predicts clinical outcome of breast cancer [ J ]. Nature, 2002,415(6871) :530-536.
  • 2Idirisinghe PK, Thike AA, Cheok PY, et al. Hormone receptorand C-ERBB2 status in distant metastatic and locally recurrentbreast cancer. Pathologic correlations and clinical significance[ J].Am J Clin Pathol,2010,133(3) :416429.
  • 3Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of dis-cordance between triple-receptor measurements in primary and re-current breast cancer[ J]. Ann Oncol,2009,20( 12) :1953-1958.
  • 4Wilking U, Karlsson E,Skoog L, et al. HER2 status in a popula-tion-derived breast cancer cohort : discordances during tumor pro-gression[ J]. Breast Cancer Res Treat,2011,125(2) :553-561.
  • 5金梁斌,汲广岩,孔令泉,刘胜春,厉红元,任国胜,吴凯南.乳腺癌雌激素受体阴性伴转移腋淋巴结受体阳性内分泌治疗一例[J].中华内分泌外科杂志,2013,7(4):348-348. 被引量:3
  • 6齐元富.乳腺癌内分泌治疗的研究进展[J].国外医学(肿瘤学分册),1998,25(1):32-34. 被引量:19
  • 7Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically usedbreast cancer markers such as estrogen receptor, progesterone re-ceptor, and human epidermal growth factor receptor 2 are unstablethroughout tumor progression [ J ]. J Clin Oncol,2012,30 ( 21 ):2601-2608.
  • 8Broom RJ,Tang PA,Simmons C, et al. Changes in estrogen re-ceptor ,progesterone receptor and Her-2/neu status with time : dis-cordance rates between primary and metastatic breast cancer [ J ].Anticancer Res,2009,29(5) : 1557-1562.
  • 9Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment ofHER2-positive breast cancer : current status and future perspectives[J]. Nat Rev Clin Oncol,2012,9( 1) : 16-32.
  • 10Sari E, Guler G, Hayran M, et al. Comparative study of the im-munohistochemical detection of hormone receptor status and HER-2expression in primary and paired recurrent/metastatic lesions of pa-tients with breast cancer[ J]. Med Oncol,2011,28( 1 ) :57-63.

二级参考文献5

  • 1Locker GY. Hormonal therapy of breast cancer[ J]. Treatment Re- view, 1998,24 ( 3 ) : 221-240.
  • 2Fraco A, Col N, Chlebowski NT. Discordancer in estrogen(ER) and progestin receptor (PR)statos between primary metastatic breast cancer, A meta-analysis [ C ]. ASC0,2004 : 539-540.
  • 3Linda Sofie Lindstrom, Eva Karlsson. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and hu- man epidermal growth factor receptor 2 are unstable throughout tumor progression [ J ]. Journal of Clinical Oncology, 2012, 30 (21) :2601-2608.
  • 4齐元富.乳腺癌内分泌治疗的研究进展[J].国外医学(肿瘤学分册),1998,25(1):32-34. 被引量:19
  • 5张德才,张景华,汪萍,何津,刘远廷,李景武.C-erbB2、PCNA、ER、PR在126例乳腺癌中的表达及临床意义[J].现代肿瘤医学,2009,17(10):1874-1877. 被引量:18

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部